Email updates

Keep up to date with the latest news and content from Alzheimer's Research & Therapy and BioMed Central.

Letter

Should persons with autosomal dominant AD be included in clinical trials?

Joshua D Grill* and John M Ringman

Author Affiliations

Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095-07226, USA

For all author emails, please log on.

Alzheimer's Research & Therapy 2011, 3:18  doi:10.1186/alzrt80


See related review by Szigeti and Doody, http://alzres.com/content/3/1/4 and related letter by Szigeti and Doody, http://alzres.com/content/3/3/19


The electronic version of this article is the complete one and can be found online at: http://alzres.com/content/3/3/18


Published:23 May 2011

© 2011 BioMed Central Ltd

Letter

In a recent issue of Alzheimer's Research & Therapy, we read with great interest the discussion by Szigeti and Doody [1] of including early-onset Alzheimer's disease (EOAD) (under age 65) in clinical trials. Successful enrollment is a challenge in most Alzheimer's disease (AD) trials, and permitting the participation of these young motivated patients could aid recruitment. EOAD can be categorized as AD caused by autosomal dominant mutations (ADAD) in the amyloid precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) genes and as AD in individuals not known or suspected to harbor such mutations, which we here refer to as sporadic AD (SAD).

We agree with the authors that SAD cases under age 65 should be included in AD trials. The literature describing these cases does not suggest that clinical or biological differences warrant exclusion. We take pause, however, with the recommendation of categorical enrollment of ADAD patients in trials. Inclusion of persons with ADAD should be dependent upon the nature of the causative mutation, the drug under investigation, and the study objectives. More than 200 AD-causing mutations are known, and predicting the impact of all disease-causing mutations on drug efficacy is difficult. APP mutations are most frequent in the β- and γ-secretase cleavage regions and result in increases in the levels of both Aβ42 and Aβ40, Aβ42 alone, or the ratio of Aβ42 to Aβ40 [2,3]. Aβ40 resultant from processing of mutated APP is resistant to degradation by neprilysin [4,5]. γ-Secretase inhibitors may lack efficacy in preventing APP cleavage by enzymes resultant from mutated PSEN genes [6,7]. On pathological examination, the brains of persons with ADAD can demonstrate atypical morphology, distribution, and composition of Aβ deposits [2]. Biological differences between ADAD and SAD might manifest similar differences in response or side-effect profile to a given intervention and thus should be considered care fully before patients with ADAD are enrolled in trials.

In phase I studies, biological differences between ADAD and SAD could translate to different dose requirements since younger patients with ADAD are likely to have a more rapid drug metabolism. Females may also be premenopausal, making teratogenicity a consideration. In phase II, differences in ADAD could have effects on outcomes and interpretation since ADAD participants might be overrepresented, given that the percentage of SAD patients who qualify for trials is low, ADAD patients have fewer barriers to participation, and trials are often conducted at academic centers where ADAD is studied. Alternatively, persons with ADAD might theoretically be enrolled in larger late-stage trials with a predefined plan to analyze efficacy and safety of this AD subtype separately. Acceptance of this approach by regulatory bodies and willingness of sponsors to risk an impact on the overall trial significance, however, are uncertain.

The Dominantly Inherited Alzheimer's Network and the Alzheimer's Prevention Initiative are preparing to conduct prevention clinical trials in ADAD, in part addressing the important need for clinical drug research in this population. These studies may not enroll persons already demented with ADAD. In accordance with the principle of beneficence, AD trial design should permit examination of efficacy in all possible disease-suffering populations. For every study, however, substantial consideration must be given to the issues of whether to include specific persons with ADAD and of how the data will be analyzed when the study is complete.

Abbreviations

AD: Alzheimer's disease; ADAD: Alzheimer's disease caused by autosomal dominant mutations; APP: amyloid precursor protein; EOAD: early-onset Alzheimer's disease; PSEN: presenilin; SAD: sporadic Alzheimer's disease.

Competing interests

JDG is the site investigator for clinical trials sponsored by Elan Corporation (Dublin, Ireland), Janssen-Cilag (a subsidiary of Johnson & Johnson, New Brunswick, NJ, USA), Bristol-Myers Squibb Company (Princeton, NJ, USA), Medivation (San Francisco, CA, USA), Pfizer Inc (New York, NY, USA), and the National Institute on Aging-sponsored Alzheimer's Disease Cooperative Study. He is the principal investigator of a clinical trial sponsored by the John Douglas French Alzheimer's Foundation (medical food generously supplied by Accera, Inc., Broomfield, CO, USA). He has received consultation fees from Avanir Pharmaceuticals (Aliso Viejo, CA, USA). JMR has received consultation fees from Takeda Pharmaceuticals Co. Ltd. (Osaka, Japan).

Acknowledgements

This work was supported by National Institute on Aging grant AG016570 and by the Sidell-Kagan Foundation.

References

  1. Szigeti K, Doody RS: Should EOAD patients be included in clinical trials?

    Alzheimers Res Ther 2011, 3:4. PubMed Abstract | Publisher Full Text OpenURL

  2. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C: Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

    Alzheimers Res Ther 2011, 3:1. PubMed Abstract | Publisher Full Text OpenURL

  3. De Strooper B: Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease.

    EMBO Rep 2007, 8:141-146. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  4. Tsubuki S, Takaki Y, Saido TC: Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation.

    Lancet 2003, 361:1957-1958. PubMed Abstract | Publisher Full Text OpenURL

  5. Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM: Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin.

    Neurobiol Dis 2008, 31:442-450. PubMed Abstract | Publisher Full Text OpenURL

  6. Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S: Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

    J Biol Chem 2007, 282:24504-24513. PubMed Abstract | Publisher Full Text OpenURL

  7. Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S: Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure.

    J Neurochem 2011, 116:385-395. PubMed Abstract | Publisher Full Text OpenURL